The respiratory segment, often influenced by seasonal factors, registered a 1.1% increase in value but faced a 4.6% decline ...

Among them, the cardiac, gastrointestinal, and antidiabetic therapies saw high value growth of 9.5 per cent, 9.6 per cent, ...

The initiatives to improve healthcare access — including Ayushman Bharat, which provides financial protection and better ...

Amoxicillin is another antibiotic in the penicillin family. It can act on bacteria both inside and outside the intestines. It’s not often used for Crohn’s disease specifically and usually ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a prescription drug on LinkedIn. A panel of leaders at the PMCPA, pharma’s ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist ...

Shares of GlaxoSmithKline Pharmaceuticals (GSK Pharma ... Notably, the company strengthened its market share in top brands like Augmentin, Ceftum and T-bact. It also expanded its presence with its ...

GSK Pharma’s flagship brands within the general medicines portfolio including Augmentin, Ceftum, and T-bact strengthened their market positions with share gains. The company’s innovative ...

The shares of GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) jumped over 15 percent to trade at Rs 2,684 apiece on February 18, extending gains for the second straight session after releasing ...